Ontology highlight
ABSTRACT: Objective
To determine the potential efficacy of ubrogepant for acute treatment of migraine based on historical experience with triptans.Background
Although triptans have improved migraine treatment, their efficacy and tolerability may limit their utility in some individuals. Ubrogepant is a small-molecule, oral calcitonin gene-related peptide receptor antagonist approved by the Food and Drug Administration for acute treatment of migraine in adults.Methods
This post hoc analysis of pooled data from the pivotal trials ACHIEVE I and II, identically designed, randomized, double-blind, phase 3, single-attack trials of ubrogepant in adults with a history of migraine with/without aura, examined the efficacy and tolerability of ubrogepant 50 mg versus placebo based on part
SUBMITTER: Blumenfeld AM
PROVIDER: S-EPMC8252782 | biostudies-literature | 2021 Mar
REPOSITORIES: biostudies-literature